Results 1 to 10 of about 10,879 (228)
Lancet Microbe, The, 2020 Summary: Background: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy.
Kimberly K Scarsi, Elizabeth E Krans
exaly +4 more sources
Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia. [PDF]
Viruses(1) Background: Hepatitis C virus (HCV) infection poses a significant health burden, particularly in Mongolia, where the HCV prevalence is notably high. This study evaluates the long-term outcomes of HCV treatment with ledipasvir/sofosbuvir, focusing on ...
Byambasuren A +4 more
europepmc +2 more sources
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
New England Journal of Medicine, 2014 BACKGROUND Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need.
Nezam Afdhal +2 more
exaly +2 more sources
F1000Research, 2020 We prepared the three-dimensional model of the 2019-nCoV 3C-like protease (3CLpro) using the crystal structure of the highly-similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are
Yu-Wei Chen, Chin-Pang Bennu Yiu
exaly +4 more sources
Liver Research, 2023 Although direct-acting antivirals (DAAs) have notably increased the sustained virological response (SVR) rates in hepatitis C virus (HCV)-infected adolescent patients, the efficacy and safety for young children under 3 years old remain unclear. Currently,
Mingna Li +4 more
doaj +2 more sources
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
New England Journal of Medicine, 2014 BACKGROUND High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir ...
Kris V Kowdley +2 more
exaly +2 more sources
F1000Research, 2020 We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen +2 more
doaj +2 more sources
Cells, 2021 The rapid spread of the virus, the surge in the number of deaths, and the unavailability of specific SARS-CoV-2 drugs thus far necessitate the identification of drugs with anti-COVID-19 activity.
Rameez Hassan Pirzada +4 more
doaj +2 more sources
Identification of novel compounds against Trypanosoma cruzi using AlphaFold structures [PDF]
Computational and Structural Biotechnology JournalChagas disease is a neglected tropical zoonosis caused by the protozoan Trypanosoma cruzi. The two approved medications for treating this disease show variable efficacy in the chronic phase, highlighting the need for new therapeutic interventions.
Albert Ros-Lucas +6 more
doaj +2 more sources
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
New England Journal of Medicine, 2014 Nezam Afdhal, Paul Y Kwo, Massimo Puoti
exaly +2 more sources